Innovating Works

AOUP

Desconocido
REVERT: taRgeted thErapy for adVanced colorEctal canceR paTients AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO PAOLO GIACCONE DI PALERMO participó en un H2020: H2020-SC1-BHC-2018-2020 The REVERT project will address the specific challenge of understanding at system level the pathophysiology of mCRC cancer in patients respo...
2019-11-22 - 2024-12-31 | Financiado
TBVAC2020: TBVAC2020 Advancing novel and promising TB vaccine candidates from discovery to preclinical and ear... AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO PAOLO GIACCONE DI PALERMO participó en un H2020: H2020-PHC-2014-2015 The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccin...
2014-12-03 - 2019-06-30 | Financiado
EMI-TB: Eliciting Mucosal Immunity to Tuberculosis AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO PAOLO GIACCONE DI PALERMO participó en un H2020: H2020-PHC-2014-2015 Tuberculosis (TB) is a global health problem, killing 1.5 million of people every year. The only currently available vaccine, Mycobacterium...
2014-11-26 - 2019-06-30 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.